“Why Korean companies ignore KRW 130 billion ‘Lipitor’”

While the complex market with statin has led the industry, Korean pharmaceutical companies are known to focus, especially, on R&D for ‘Crestor(generic name: rosuvastatin).’

In this way, the market of combined drugs with statin is mostly divided into rosuvastatin and atorvastatin. Moreover, Korean companies preferred rosuvastatin over atorvastatin.

Thus, fierce competition was inevitable in t...